Navigation Links
Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
Date:7/7/2011

ANAHEIM, Calif., July 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2011 financial results  on Tuesday, July 26, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and webcast on Tuesday, July 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the second quarter, as well as current corporate developments.  Conference call details:Date:

Tuesday, July 26, 2011Time:

4:30 p.m. ETDial-in (U.S.):

877-941-8609Dial-in (International):

480-629-9818Web cast:

www.questcor.comTo access an audio replay of the call:Replay (U.S.):

800-406-7325Replay (International):

303-590-3030Replay Passcode:

4455547About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
2. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
3. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
4. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
5. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
6. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
7. Questcor Pharmaceuticals Selects BDO USA as its Auditor
8. Questcor Reports 2010 Financial Results
9. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
10. Questcor Pharmaceuticals Reports Strong Finish to 2010
11. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Ga., Feb. 27, 2017 Halyard Health, Inc. (NYSE: ... 2016 results and provided its 2017 outlook and related key ... sales were $410 million, a 2 percent increase compared to ... fourth quarter 2016 was $10 million compared to net income ... quarter adjusted net income was $24 million compared to adjusted ...
(Date:2/27/2017)... , Feb. 27, 2017   Royal ... PHIA), a global leader in health technology, today ... Drug Administration (FDA) to market its ElastQ Imaging ... family of ultrasound systems. ElastQ Imaging enables simultaneous ... which is essential for the diagnosis of various ...
(Date:2/27/2017)... -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) will ... Annual Healthcare Conference on Monday, March 6, 2017, ... A live webcast of Infinity,s presentation will ... at www.infi.com , and will be available for ... is an innovative biopharmaceutical company dedicated to advancing novel ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... 28, 2017 , ... Roxanna Cross will host a key ... Annual RISE Nashville Summit. RISE Nashville is the healthcare industry’s premier event addressing ... The discussion will include best practices for accurate identification and capture of population ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation in ... body, these individual customized retreats offer the winter-weary soul an excellent opportunity to ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... therapy, is proud to announce a new informational post on robotic hair transplantation. ... Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 INAB ... (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets ...
Breaking Medicine News(10 mins):